Arvinas, Inc. (ARVN)

NASDAQ • Healthcare

$7.3

-$0.41 (-5.4%)

Market closed

Last close at October 23, 2026 at 20:00 UTC

Open$7.7

Day Range$7.2 - $7.7

Avg. Volume (3M)684.8K

Market Cap$471M

P/E Ratio38.4

52 Week Range

$6.74$14.51

Next EarningsIn 10 daysNov 4, 2026

Metrics Over Time

Where the Money Goes

Q2 2026

Revenueeverything earned$249.7M100%

Gross Profitminus cost of goods$240.7M96%

Operating Incomeminus R&D and overhead$164.1M66%

Net Incomeminus taxes and the rest$169.4M68%

In plain terms: out of every $100 in revenue, Arvinas, Inc. keeps $68 as net profit.

Fundamentals & Financials

Revenue (TTM)

$316.7M

Net Income (TTM)

$9.3M

EPS (TTM)

$0.19

ROA (TTM)

1.38%

Current Ratio

7.91

TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.

Income Statement

Balance Sheet

Financial Highlights

Dividends History

Split History

Earnings

+3.4%Q3 2025-$0.84

+36.0%Q4 2025-$0.48

-100.0%Q1 2026-$1.1

+5.3%Q2 2026-$0.9

+789.6%Q3 2026$2.58

Nov 4

in 10 daysQ4 2026

% — EPS deviation from the forecast (beat / miss); quarters without a forecast show the reported EPS

Latest report — Q3 2026

Beat +789.6%

Arvinas’ second fiscal quarter of 2026 featured negative operating cash flow, with operating cash flow at -$48.3 million, as it continued to fund development of its targeted protein degradation programs; the company reported the results on August 4, 2026. Looking ahead, next-period consensus calls for EPS of -$0.87 on revenue of $16.8 million.

Next report — what to expect

Arvinas, Inc. (ARVN) reports next on November 4, 2026. With consensus figures not provided here, traders may focus on the setup into the print and management’s updates on key programs. Historically, Arvinas has beaten EPS in 7 of 8 most recent quarters, which can shape expectations for the release.

View full earnings history

About Arvinas, Inc.

Arvinas, Inc. is a NASDAQ-listed biotechnology company that develops protein-degradation medicines aimed at eliminating disease-causing proteins. Its business centers on identifying, advancing, and marketing these therapies, and it generated $262.6 million of revenue in FY2025 through a model built around partnered drug development and clinical-stage candidates.

Name

Arvinas, Inc.

CEO

Randy Teel

Website

www.arvinas.com

Industry

Healthcare

Year Founded

2013

Employees

246

Today's Snapshot

AI-generated

The day ended with ARVN 5.4% lower at 7.30, in line with a weaker sector. ARVN reports earnings on 4 November.

Trading Volume

Below 10d avg (680.6K)

651.4K

vs S&P 500 Today

Strong Underperformance

-4.92%

Updated: October 23, 2026 at 20:16 UTC

Technical Indicators

0 Buy3 Neutral5 Sell

ARVN presents a sell stance with the stock trading around 7.30 and clearly below several medium- and long-term moving averages, including the 200-day near 9.80, which highlights longer-term weakness. Short-term indicators are mixed and momentum is slightly negative, while ADX remains subdued, indicating no strong directional trend. Volume readings show a large OBV but are flagged as unfavorable, suggesting the recent price action lacks healthy accumulation. The pivot around 7.62 is above the market and aligns with short-term resistance. Technical takeaway: sell—price undercuts major averages with weak momentum and unfavorable volume dynamics.

All signals

EMA (5 indicators)$7.40 - $9.61
Sell
RSI (14)44.01
Neutral
Stochastic %K (14, 3, 3)74.92
Neutral
MACD Level (12, 26)-0.21
Neutral

Peers & Related Assets

KYMRKymera Therapeutics, Inc.

$110.76-0.1%

NRIXNurix Therapeutics, Inc.

$25.34-0.7%

GLUEMonte Rosa Therapeutics, Inc.

$10.84-2.4%

CCCCC4 Therapeutics, Inc.

FHTXFoghorn Therapeutics Inc.

Stay Ahead of the Market

Get premium market insights delivered directly to your inbox.